Cargando…

Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency

BACKGROUND: Hypopituitarism and obesity are causes of major lifelong morbidity in patients with optic nerve hypoplasia (ONH). Growth hormone deficiency (GHD) affects the majority of children with ONH, though the degree of deficiency and variability of early growth patterns range from early severe re...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, Carly, Garcia-Filion, Pamela, Fink, Cassandra, Ryabets-Lienhard, Anna, Geffner, Mitchell E., Borchert, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774157/
https://www.ncbi.nlm.nih.gov/pubmed/26937243
http://dx.doi.org/10.1186/s13633-016-0023-9
_version_ 1782418868877131776
author Stewart, Carly
Garcia-Filion, Pamela
Fink, Cassandra
Ryabets-Lienhard, Anna
Geffner, Mitchell E.
Borchert, Mark
author_facet Stewart, Carly
Garcia-Filion, Pamela
Fink, Cassandra
Ryabets-Lienhard, Anna
Geffner, Mitchell E.
Borchert, Mark
author_sort Stewart, Carly
collection PubMed
description BACKGROUND: Hypopituitarism and obesity are causes of major lifelong morbidity in patients with optic nerve hypoplasia (ONH). Growth hormone deficiency (GHD) affects the majority of children with ONH, though the degree of deficiency and variability of early growth patterns range from early severe retardation to normal initial growth. The utility of early GH replacement for improving anthropometric, body composition, and lipid outcomes in patients with ONH and GHD, especially those with normal initial height velocity, is unknown. This study examines the effects of GH replacement in a cohort of children with ONH and GHD. METHODS: Controlled clinical trial from 2005–2014. The study included 17 children with ONH and untreated GHD. Those meeting criteria for growth deceleration were assigned to treatment with recombinant human growth hormone (n = 5) while those with normal height velocity were randomized either to treatment (n = 5) or to observation (no intervention, n = 7). Study duration was 3 years. Primary outcome measures included stature, weight, weight-for-stature, and BMI standard deviation score (SDS) at study completion. RESULTS: Subjects on GH, irrespective of entry growth trajectory, grew more on average in stature than controls by a difference of 0.98 SDS by study end; this effect persisted after adjusting for baseline overweight status. Treatment had an effect on weight SDS only after adjusting for initial overweight status, resulting in an average increase of 0.83 SDS more than controls. Subjects who were overweight at the outset experienced greater gains in both weight and stature SDS. Treatment had no statistically significant impact on weight-for-stature or BMI SDS. A reduction in body fat percentage was observed in those treated, both before (−6.1 %) and after (−4.3 %) adjustment for initial overweight status. CONCLUSION: Early GH replacement has a positive effect on short-term statural outcomes in children with ONH and GHD, even in those exhibiting normal initial linear growth. Results were less conclusive regarding treatment effects on body composition and lipids.
format Online
Article
Text
id pubmed-4774157
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47741572016-03-03 Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency Stewart, Carly Garcia-Filion, Pamela Fink, Cassandra Ryabets-Lienhard, Anna Geffner, Mitchell E. Borchert, Mark Int J Pediatr Endocrinol Research BACKGROUND: Hypopituitarism and obesity are causes of major lifelong morbidity in patients with optic nerve hypoplasia (ONH). Growth hormone deficiency (GHD) affects the majority of children with ONH, though the degree of deficiency and variability of early growth patterns range from early severe retardation to normal initial growth. The utility of early GH replacement for improving anthropometric, body composition, and lipid outcomes in patients with ONH and GHD, especially those with normal initial height velocity, is unknown. This study examines the effects of GH replacement in a cohort of children with ONH and GHD. METHODS: Controlled clinical trial from 2005–2014. The study included 17 children with ONH and untreated GHD. Those meeting criteria for growth deceleration were assigned to treatment with recombinant human growth hormone (n = 5) while those with normal height velocity were randomized either to treatment (n = 5) or to observation (no intervention, n = 7). Study duration was 3 years. Primary outcome measures included stature, weight, weight-for-stature, and BMI standard deviation score (SDS) at study completion. RESULTS: Subjects on GH, irrespective of entry growth trajectory, grew more on average in stature than controls by a difference of 0.98 SDS by study end; this effect persisted after adjusting for baseline overweight status. Treatment had an effect on weight SDS only after adjusting for initial overweight status, resulting in an average increase of 0.83 SDS more than controls. Subjects who were overweight at the outset experienced greater gains in both weight and stature SDS. Treatment had no statistically significant impact on weight-for-stature or BMI SDS. A reduction in body fat percentage was observed in those treated, both before (−6.1 %) and after (−4.3 %) adjustment for initial overweight status. CONCLUSION: Early GH replacement has a positive effect on short-term statural outcomes in children with ONH and GHD, even in those exhibiting normal initial linear growth. Results were less conclusive regarding treatment effects on body composition and lipids. BioMed Central 2016-03-02 2016 /pmc/articles/PMC4774157/ /pubmed/26937243 http://dx.doi.org/10.1186/s13633-016-0023-9 Text en © Stewart et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Stewart, Carly
Garcia-Filion, Pamela
Fink, Cassandra
Ryabets-Lienhard, Anna
Geffner, Mitchell E.
Borchert, Mark
Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency
title Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency
title_full Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency
title_fullStr Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency
title_full_unstemmed Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency
title_short Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency
title_sort efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774157/
https://www.ncbi.nlm.nih.gov/pubmed/26937243
http://dx.doi.org/10.1186/s13633-016-0023-9
work_keys_str_mv AT stewartcarly efficacyofgrowthhormonereplacementonanthropometricoutcomesobesityandlipidsinchildrenwithopticnervehypoplasiaandgrowthhormonedeficiency
AT garciafilionpamela efficacyofgrowthhormonereplacementonanthropometricoutcomesobesityandlipidsinchildrenwithopticnervehypoplasiaandgrowthhormonedeficiency
AT finkcassandra efficacyofgrowthhormonereplacementonanthropometricoutcomesobesityandlipidsinchildrenwithopticnervehypoplasiaandgrowthhormonedeficiency
AT ryabetslienhardanna efficacyofgrowthhormonereplacementonanthropometricoutcomesobesityandlipidsinchildrenwithopticnervehypoplasiaandgrowthhormonedeficiency
AT geffnermitchelle efficacyofgrowthhormonereplacementonanthropometricoutcomesobesityandlipidsinchildrenwithopticnervehypoplasiaandgrowthhormonedeficiency
AT borchertmark efficacyofgrowthhormonereplacementonanthropometricoutcomesobesityandlipidsinchildrenwithopticnervehypoplasiaandgrowthhormonedeficiency